You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

Tolinapant Targeted Therapy with Chemotherapy for Women with Advanced Triple Negative Breast Cancer

Phase I/Ib Study of Eribulin in Combination With ASTX660 (Tolinapant) in Metastatic Triple Negative Breast Cancer (TNBC)

Purpose: To study the safety, best dose, and effects (good and bad) of tolinapant (ASTX660), an experimental targeted therapy, with eribulin (Halaven®) chemotherapy.

Who is this for?: Women with advanced (some stage III) or metastatic (stage IV) triple negative (ER- or ER low, PR- or PR low, HER2- or HER2 low) breast cancer who have received at least 2 lines of treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tolinapant (ASTX660), by mouth, daily, 1 week on, 1 week off</li> <li class="seamTextUnorderedListItem">Eribulin (Halaven®), by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">CT scans</li> <li class="seamTextUnorderedListItem">MRI scans</li> <li class="seamTextUnorderedListItem">X-ray scans</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tolinapant (ASTX660) is an experimental targeted therapy drug that may stop the growth of tumor cells by blocking proteins, such as XIAP and cIAP1, needed for tumor cell survival.</li> <li class="seamTextUnorderedListItem">Chemotherapy drugs, such as eribulin (Halaven®), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or IHC 2+/FISH-.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06590558' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://astx.com/research-development/clinical-pipeline/tolinapant-astx660-dual-iap-antagonist-t-cell-lymphomas/' target='_blank'>Astex Pharmaceuticals: Tolinapant (ASTX660) Drug Information Page</a> </li></ul>
1

Tolinapant Targeted Therapy with Chemotherapy for Women with Advanced Triple Negative Breast Cancer

Phase I/Ib Study of Eribulin in Combination With ASTX660 (Tolinapant) in Metastatic Triple Negative Breast Cancer (TNBC)
Icon

Nearest Location:
2108 miles
Ohio State University Comprehensive Cancer Center LAO
Columbus, OH

Icon

Visits:
At least 1 visit every 2 weeks

Icon

ClinicalTrials.gov: NCT06590558

Icon

Phase I

HELP GUIDE
HELP GUIDE